Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01460238 |
Recruitment Status :
Completed
First Posted : October 26, 2011
Last Update Posted : March 28, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Chronic Lymphocytic Leukemia |
Study Type : | Observational |
Actual Enrollment : | 29 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia |
Study Start Date : | October 2011 |
Actual Primary Completion Date : | May 2018 |
Actual Study Completion Date : | May 2018 |

Group/Cohort |
---|
No treatment
No intervention. Each patient will have blood drawn at a standard of care venipuncture.
|
- LPL Protein Expression [ Time Frame: 1 year ]Determine the degree of LPL protein expression in CLL cells using a novel LPL antibody, correlate with IgHV mutation status, and compare this association with other prognostic markers
- Fatty acid acquisition and synthesis [ Time Frame: 1 year ]Demonstrate that CLL cells also possess the enzymatic machinery for fatty acid acquisition and synthesis as shown by the expression of LPL, CD36, SDC1, and fatty acid synthase
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Diagnosis of CLL as per National Cancer Institute Working Group Guidelines
- Patients undergoing routine blood draws as part of their ongoing follow up for CLL
- 18 years or older
- Ability to provide consent in English
- Patient must have measurable disease as defined by an absolute lymphocyte count greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL involvement.
Exclusion Criteria:
- Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for their CLL,
- other hematologic malignancy or other disease process within the past 6 months are excluded.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01460238
United States, New Hampshire | |
Dartmouth-Hitchcock Medical Center | |
Lebanon, New Hampshire, United States, 03756 |
Principal Investigator: | Frederick Lansigan, MD | Dartmouth-Hitchcock Medical Center |
Responsible Party: | Frederick Lansigan, Assistant Professor of Medicine, Dartmouth-Hitchcock Medical Center |
ClinicalTrials.gov Identifier: | NCT01460238 |
Other Study ID Numbers: |
D11065 |
First Posted: | October 26, 2011 Key Record Dates |
Last Update Posted: | March 28, 2019 |
Last Verified: | March 2019 |
Lipoprotein Lipase Chronic Lymphocytic Leukemia CLL |
Leukemia Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Leukemia, B-Cell |